Tekla Price To Sales Ratio from 2010 to 2024
| HQL Stock | USD 13.79 0.04 0.29% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 16.33 | Current Value 15.52 | Quarterly Volatility 192.64540328 |
Check Tekla Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Life's main balance sheet or income statement drivers, such as Depreciation And Amortization of 183.4 K, Interest Expense of 0.0 or Total Revenue of 28.4 M, as well as many indicators such as Price To Sales Ratio of 15.52, Dividend Yield of 0.0 or PTB Ratio of 0.92. Tekla financial statements analysis is a perfect complement when working with Tekla Life Valuation or Volatility modules.
Tekla | Price To Sales Ratio |
Latest Tekla Life's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Tekla Life Sciences over the last few years. Price to Sales Ratio is figured by comparing Tekla Life Sciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tekla Life sales, a figure that is much harder to manipulate than other Tekla Life Sciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Tekla Life's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Life's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 107.36 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Tekla Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 116.65 | |
| Coefficient Of Variation | 165.14 | |
| Mean Deviation | 152.61 | |
| Median | 15.29 | |
| Standard Deviation | 192.65 | |
| Sample Variance | 37,112 | |
| Range | 594 | |
| R-Value | (0.63) | |
| Mean Square Error | 23,880 | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (27.33) | |
| Total Sum of Squares | 519,572 |
Tekla Price To Sales Ratio History
About Tekla Life Financial Statements
Tekla Life investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Tekla Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 16.33 | 15.52 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Tekla Life Correlation against competitors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.425 | Dividend Share 1.3 | Earnings Share 1.34 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.07 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.